Malley Thomas 4

What Happened

• Malley Thomas, a director of Kura Oncology, exercised stock options on 2026-03-18 to acquire a total of 20,000 shares. He paid $3.12 per share for 10,000 shares (cash outlay $31,200) and acquired an additional 10,000 shares with $0 cash consideration (conversion of a derivative).
• This is an acquisition (exercise of options), not a sale; the Form 4 reports the shares were acquired rather than sold.

Key Details

• Transaction date: 2026-03-18 (reported on Form 4 filed 2026-03-20 — appears timely).
• Prices and counts: 10,000 shares at $3.12 ($31,200); 10,000 shares at $0.00 (no cash paid).
• Total shares acquired: 20,000; total cash paid (per filing): $31,200.
• Transaction code: M (exercise/conversion of derivative).
• Shares owned after transaction: not disclosed in the excerpt of this filing.
• Footnotes from the filing:
  • F1: These were stock options exercised.
  • F2: Mr. Malley serves as President of Mossrock Capital, LLC and has sole voting and investment power over these shares.
  • F3: The option is fully vested.
• No immediate sale or cashless disposition is reported on this Form 4.

Context

• For retail investors: this filing documents an option exercise — the insider acquired shares, which is generally more informative than routine sales but does not by itself indicate future company performance.
• One tranche shows a $0 strike/consideration (a non‑cash conversion), which can reflect option terms or prior grant mechanics; the other tranche required cash payment.
• Because the filing was timely and no sale is listed, the newly acquired shares appear to be held rather than immediately sold.